Subacute toxicity testing is a repeated-dose systemic toxicity study that evaluates potential adverse health effects of medical devices or their extracts after 14 to 28 days of exposure. Performed in accordance with ISO 10993-11 and the risk-based framework of ISO 10993-1, this study type is a core component of the biological evaluation for devices with prolonged or long-term patient contact. This article provides a technical overview of the principles, sample requirements, test items, methodology, and applications of subacute toxicity testing for medical devices.
Technical Overview
Subacute toxicity testing, also referred to as repeated-dose systemic toxicity testing, is designed to characterize harmful effects that may arise from daily or repeated exposure to the leachable substances released by a medical device over a period of 14 to 28 days. Unlike single-exposure acute toxicity studies, subacute studies reveal cumulative target-organ toxicity, physiological adaptation, and dose-response relationships that only become apparent after repeated administration.
The primary international standard governing this evaluation is ISO 10993-11, which is harmonized in China as GB/T 16886.11. Study design is supported by ISO 10993-1 (evaluation framework within risk management), ISO 10993-2 (animal welfare requirements and the 3Rs principles), ISO 10993-12 (sample preparation and reference materials), and ISO 10993-17 (toxicological risk assessment). Methodological elements are also aligned with OECD Test Guideline 407 for repeated-dose toxicity studies, adapted for medical device extracts and materials.
Within the ISO 10993-1 contact classification system, subacute toxicity testing is typically considered for devices with prolonged contact (24 hours to 30 days) or long-term contact (more than 30 days), particularly when the device has blood contact, is implantable, or releases extractables whose toxicological profile is not fully characterized through chemical analysis alone.
Distinguishing Subacute from Related Study Types
Systemic toxicity studies form a continuum based on exposure duration: acute toxicity involves a single exposure or multiple exposures within 24 hours; subacute toxicity involves repeated exposure for 14 to 28 days; subchronic toxicity extends over approximately 90 days; and chronic toxicity covers a substantial portion of the animal's lifespan. Selecting the correct study type depends on the intended clinical contact duration of the device and on the results of prior chemical characterization and risk assessment.
Testing Samples
Test articles for subacute toxicity testing are generally prepared from the final finished device, including all materials, processing aids, and sterilization residues, because manufacturing and sterilization can significantly alter the extractable profile. When a finished device cannot be extracted intact, representative coupons of each material are tested at their worst-case production condition.
Device Categories Commonly Evaluated
- Intravascular catheters, infusion sets, syringes, and blood administration sets
- Hemodialyzers, extracorporeal circuits, and blood oxygenators
- Short-term and long-term implants such as orthopedic fixation devices, stents, and drug-delivery components
- Wound dressings, absorbable hemostats, and tissue adhesives with prolonged mucosal or breached-skin contact
- Devices made from novel polymers, bioresorbable materials, or materials with unknown leachable profiles
Extracts and Test Articles
Because devices cannot be dosed directly, subacute studies typically use polar and non-polar extracts. The polar vehicle is commonly physiological saline or saline with suitable solubilizers, while the non-polar vehicle is typically sesame oil or another vegetable oil. Both extract classes are tested concurrently to capture the full range of hydrophilic and lipophilic leachables. In some study designs, fine particles or direct implantation of the device material may be evaluated when extraction alone does not adequately represent clinical exposure.
Testing Items
A comprehensive subacute toxicity study evaluates functional, biochemical, and morphological endpoints to identify target organs and establish a no-observed-adverse-effect level where achievable. Standard test items include:
- Mortality and daily clinical observations, including signs of local intolerance at injection sites
- Body weight measurement at baseline and at scheduled intervals throughout the study
- Food and water consumption monitoring
- Functional observations, including sensory reactivity and grip strength in extended designs
- Hematology: erythrocyte count, leukocyte count with differential, hemoglobin, hematocrit, MCV, MCH, MCHC, platelet count, and coagulation parameters such as prothrombin time and activated partial thromboplastin time
- Clinical chemistry: ALT, AST, ALP, GGT, total bilirubin, urea, creatinine, glucose, total protein, albumin, globulin, cholesterol, triglycerides, and electrolytes including sodium, potassium, calcium, and chloride
- Urinalysis: volume, specific gravity, pH, protein, glucose, ketones, and occult blood
- Terminal body weight, gross necropsy, and organ weights for liver, kidneys, adrenals, heart, lungs, brain, spleen, thymus, and reproductive organs
- Comprehensive histopathological examination of major organs, tissues, and dosing sites
Testing Methods
Sample Preparation
Extraction is performed according to ISO 10993-12 using standardized ratios, such as 3 cm²/mL or 6 cm²/mL of extraction vehicle based on material thickness, or approximately 0.1 to 0.2 g/mL for irregular solids and elastomers. Extraction conditions are selected to maximize leachable release without degrading the material, with common conditions including 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour. Extracts are administered promptly after preparation, and vehicles are sterilized by appropriate methods such as membrane filtration before use.
Study Design and Dosing
The typical study uses healthy young adult rodents, most commonly Sprague Dawley or Wistar rats, with at least five animals per sex per group. Groups include a vehicle control, a polar extract group, and a non-polar extract group; additional groups may include a sham control or multiple dose levels. Extracts are administered once daily for 14 to 28 consecutive days by the route most relevant to clinical exposure, commonly intravenous injection for polar extracts and intraperitoneal, subcutaneous, or intramuscular injection for non-polar extracts. Dose volumes are selected according to route-specific limits, for example up to 10 mL/kg for intravenous administration in rodents, adjusted to ensure animal welfare while delivering the maximum practical dose of leachables.
Observation, Analysis, and Reporting
Clinical observations and mortality checks are performed at least once daily, with body weight and food consumption recorded weekly. Blood and urine samples are collected at termination for laboratory analysis, followed by gross necropsy, organ weighing, and histopathology. Statistical comparisons between extract groups and vehicle controls are performed to identify both statistically and biologically significant differences. The final report documents study design, observations, all analytical data, pathological findings, and a conclusion regarding the systemic toxicity potential of the device, including identification of target organs and any no-observed-adverse-effect level.
Applications
Subacute toxicity data serve multiple purposes across the medical device product lifecycle:
- Regulatory submissions for device registration with national medical device authorities, including premarket review in major jurisdictions and technical documentation under the EU MDR
- Biological safety evaluation files demonstrating conformity with the ISO 10993 series for prolonged-contact and long-term contact devices
- Supplementary toxicological evidence when chemical characterization and ISO 10993-17 risk assessment cannot fully close safety questions about complex leachable mixtures
- Evaluation of new materials, alternative polymers, or changes in sterilization method, manufacturing process, or supplier that could alter the extractable profile
- Justification within risk management documentation, per ISO 14971, for waiving longer-duration subchronic or chronic studies when subacute results demonstrate an adequate margin of safety
- Support for preclinical development of combination products and drug-device interfaces
Accredited third-party laboratories with GLP-compliant facilities are frequently engaged to conduct these studies, ensuring data quality and acceptance by regulatory reviewers worldwide.
FAQ
What is the difference between subacute and subchronic toxicity testing?
The distinction lies in exposure duration. Subacute studies involve repeated dosing for 14 to 28 days, while subchronic studies last approximately 90 days. Subacute studies are generally selected for devices with clinical contact of up to about one month, whereas subchronic or chronic studies support longer-term implants.
When is subacute toxicity testing required for a medical device?
It is typically required when a device has prolonged contact of 24 hours to 30 days or long-term contact exceeding 30 days, especially for blood-contacting, implantable, or drug-delivering devices, and when chemical characterization cannot rule out systemic risk from leachables.
Which standards govern the test?
The core standard is ISO 10993-11 for systemic toxicity, supported by ISO 10993-1, ISO 10993-2, ISO 10993-12, and ISO 10993-17. The Chinese national adoption is GB/T 16886.11, and methodology aligns closely with OECD Test Guideline 407.
What animals are used, and how many?
Healthy young adult rodents, most commonly rats, are used with at least five animals per sex per group, including vehicle controls. Species selection must be justified relative to the route of administration and the metabolism of expected leachables.
How are device extracts administered?
Polar extracts, usually in saline, are commonly injected intravenously to simulate blood contact, while non-polar extracts in vegetable oil are administered intraperitoneally, subcutaneously, or intramuscularly. Dosing occurs once daily for the full study duration at route-appropriate volumes.
How long does the overall testing process take?
Excluding protocol preparation and animal acclimation, the in-life phase lasts 14 to 28 days, and complete analysis including histopathology typically extends the total study duration to approximately eight to twelve weeks before the final report is issued.